We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
Read MoreHide Full Article
Key Takeaways
Agilent earned $1.37 per share in fiscal Q3, up 3.8% year over year, topping consensus estimates.
Revenues rose 10.1% to $1.74B, driven by growth across LDG, ACG, and AMG segments.
Agilent sees Q4 revenue up as much as 8.3% and FY25 EPS between $5.56 and $5.59.
Agilent Technologies (A - Free Report) reported third-quarter fiscal 2025 earnings of $1.37 per share, which beat the Zacks Consensus Estimate by 0.74%. The figure increased 3.8% year over year.
Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 4.6%. The top line increased 10.1% on a reported basis and 8% on a core basis (excluding acquisitions and divestitures) year over year.
Agilent shares are up 3.3% at the time of writing this article. A shares have dropped 8.4% compared with the Zacks Medical sector’s fall of 2.5%.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
The company operates through three reporting segments—Life Sciences and Diagnostics Markets Group (“LDG”), Agilent CrossLab Group (“ACG”) and Applied Markets Group (“AMG”).
LDG: The segment generated $670 million and accounted for 38.6% of the company’s total revenues. This represented a 14.5% increase on a reported basis and 9% rise on a core basis year over year.
ACG: Revenues from the segment were $744 million, accounting for 42.8% of the total revenues. The top line grew 7.7% on a reported basis and 8% on a core basis year over year.
AMG: Revenues increased 7.3% year over year to $324 million on a reported and 7% on a core basis, accounting for the remaining 18.6% of the total revenues.
Agilent’s Q3 Operating Results
For the third quarter of fiscal 2025, the LDG segment’s gross margin contracted 390 basis points (bps) year over year to 50.5%. ACG’s gross margin decreased 260 bps year over year to 55.1%, while AMG’s gross margin declined 160 bps year over year to 53.6%.
Research and development (R&D) expenses on a non-GAAP basis were $109 million, down 3.5% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose slightly to $374 million, marking a 2.2% increase from the prior-year quarter.
As a percentage of revenues, Research and development expenses fell 50 bps year over year to 6.3%, while selling, general and administrative expenses fell 30 bps year over year to 21.6%.
The non-GAAP operating margin of 25.1% for the fiscal third quarter contracted 220 bps on a year-over-year basis.
Segment-wise, LDG operating margin decreased 190 bps year over year to 17.6%. ACG’s operating margin fell 260 bps year over year to 33.3%. Meanwhile, AMG’s operating margin contracted 130 bps year over year to 21.9%.
A’s Balance Sheet Details
As of July 31, 2025, Agilent’s cash and cash equivalents were $1.54 billion, up from $1.49 billion as of April 30.
The long-term debt was $3.35 billion as of July 31, 2025, unchanged sequentially.
Agilent’s Q4 & FY25 Guidance
For the fourth quarter of fiscal 2025, Agilent expects revenues of $1.822-$1.842 billion, indicating a rise of 7.1% to 8.3% on a reported basis and 4.8% to 6% on a core basis. Non-GAAP earnings are expected between $1.57 per share and $1.60 per share.
For fiscal 2025, Agilent expects revenues between $6.91 billion and $6.93 billion, implying an increase of 6.2-6.5% on a reported basis and 4.3-4.6% on a core basis. The company expects non-GAAP earnings between $5.56 per share and $5.59 per share.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #3 (Hold).
Astrana Health (ASTH - Free Report) , Syndax Pharmaceuticals (SNDX - Free Report) and Phibro Animal Health (PAHC - Free Report) are some better-ranked stocks that investors can consider in the broader sector.
Astrana Health sports a Zacks Rank #1 (Strong Buy), while Syndax Pharmaceuticals and Phibro Animal Health each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for Astrana Health, Syndax Pharmaceuticals and Phibro Animal Health is currently pegged at 29.68%, 27.29% and 25.99%, respectively.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
Key Takeaways
Agilent Technologies (A - Free Report) reported third-quarter fiscal 2025 earnings of $1.37 per share, which beat the Zacks Consensus Estimate by 0.74%. The figure increased 3.8% year over year.
Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 4.6%. The top line increased 10.1% on a reported basis and 8% on a core basis (excluding acquisitions and divestitures) year over year.
Agilent shares are up 3.3% at the time of writing this article. A shares have dropped 8.4% compared with the Zacks Medical sector’s fall of 2.5%.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote
Agilent’s Q3 Top-Line Details
The company operates through three reporting segments—Life Sciences and Diagnostics Markets Group (“LDG”), Agilent CrossLab Group (“ACG”) and Applied Markets Group (“AMG”).
LDG: The segment generated $670 million and accounted for 38.6% of the company’s total revenues. This represented a 14.5% increase on a reported basis and 9% rise on a core basis year over year.
ACG: Revenues from the segment were $744 million, accounting for 42.8% of the total revenues. The top line grew 7.7% on a reported basis and 8% on a core basis year over year.
AMG: Revenues increased 7.3% year over year to $324 million on a reported and 7% on a core basis, accounting for the remaining 18.6% of the total revenues.
Agilent’s Q3 Operating Results
For the third quarter of fiscal 2025, the LDG segment’s gross margin contracted 390 basis points (bps) year over year to 50.5%. ACG’s gross margin decreased 260 bps year over year to 55.1%, while AMG’s gross margin declined 160 bps year over year to 53.6%.
Research and development (R&D) expenses on a non-GAAP basis were $109 million, down 3.5% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose slightly to $374 million, marking a 2.2% increase from the prior-year quarter.
As a percentage of revenues, Research and development expenses fell 50 bps year over year to 6.3%, while selling, general and administrative expenses fell 30 bps year over year to 21.6%.
The non-GAAP operating margin of 25.1% for the fiscal third quarter contracted 220 bps on a year-over-year basis.
Segment-wise, LDG operating margin decreased 190 bps year over year to 17.6%. ACG’s operating margin fell 260 bps year over year to 33.3%. Meanwhile, AMG’s operating margin contracted 130 bps year over year to 21.9%.
A’s Balance Sheet Details
As of July 31, 2025, Agilent’s cash and cash equivalents were $1.54 billion, up from $1.49 billion as of April 30.
The long-term debt was $3.35 billion as of July 31, 2025, unchanged sequentially.
Agilent’s Q4 & FY25 Guidance
For the fourth quarter of fiscal 2025, Agilent expects revenues of $1.822-$1.842 billion, indicating a rise of 7.1% to 8.3% on a reported basis and 4.8% to 6% on a core basis. Non-GAAP earnings are expected between $1.57 per share and $1.60 per share.
For fiscal 2025, Agilent expects revenues between $6.91 billion and $6.93 billion, implying an increase of 6.2-6.5% on a reported basis and 4.3-4.6% on a core basis. The company expects non-GAAP earnings between $5.56 per share and $5.59 per share.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #3 (Hold).
Astrana Health (ASTH - Free Report) , Syndax Pharmaceuticals (SNDX - Free Report) and Phibro Animal Health (PAHC - Free Report) are some better-ranked stocks that investors can consider in the broader sector.
Astrana Health sports a Zacks Rank #1 (Strong Buy), while Syndax Pharmaceuticals and Phibro Animal Health each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for Astrana Health, Syndax Pharmaceuticals and Phibro Animal Health is currently pegged at 29.68%, 27.29% and 25.99%, respectively.